Add to ORKGProstate specific antigen (PSA) is a biomarker for prostate cancer (PCa) that is widely used for PCa screening. Using a database of 2415 men included in the Spanish screening arm of the ERSPC Study, we will use joint modelling strategies to analyze if longitudinal PSA profiles and time to PCa incidence allow to obtain a better estimate of the individual risk of PCa. Conclusions and limitations of the study will be discussed.Peer Reviewe
International audienceBACKGROUND: Tools for differentiating aggressive and indolent prostate carcino...
textabstractBackground: Prostate-specific antigen (PSA) testing has limited accuracy for the early d...
Prostate cancer (PCa) screening remains a controversial topic. The value of population-based screeni...
Prostate specific antigen (PSA) is a biomarker for prostate cancer (PCa) that is widely used for PCa...
The paper describes the use of frequentist and Bayesian shared-parameter joint models of longitudina...
The paper describes the use of frequentist and Bayesian shared-parameter joint models of longitudina...
The objective was to determine the association between prostate specific antigen (PSA) predictors an...
Prostate Specific Antigen (PSA) is a biochemical marker used to monitor prostate cancer following tr...
Background: Prostate-specifi c antigen (PSA) testing is the pri-mary method used to diagnose prostat...
Prostate specific antigen (PSA) is a common biomarker used to aid detection of prostate cancer (PCa)...
Among different types of cancers which occur in men, prostate cancer is the most commonly occurring ...
BackgroundFor men on active surveillance for prostate cancer, utility of prostate-specific antigen (...
International audienceBACKGROUND:Despite the extensive development of risk prediction models to aid ...
textabstractObjective To assess the value added by percentage of free to total PSA (%fPSA), prostate...
(a) Nomogram for PCa risk prediction of benign prostatic hyperplasia patients. (b) The predicted pro...
International audienceBACKGROUND: Tools for differentiating aggressive and indolent prostate carcino...
textabstractBackground: Prostate-specific antigen (PSA) testing has limited accuracy for the early d...
Prostate cancer (PCa) screening remains a controversial topic. The value of population-based screeni...
Prostate specific antigen (PSA) is a biomarker for prostate cancer (PCa) that is widely used for PCa...
The paper describes the use of frequentist and Bayesian shared-parameter joint models of longitudina...
The paper describes the use of frequentist and Bayesian shared-parameter joint models of longitudina...
The objective was to determine the association between prostate specific antigen (PSA) predictors an...
Prostate Specific Antigen (PSA) is a biochemical marker used to monitor prostate cancer following tr...
Background: Prostate-specifi c antigen (PSA) testing is the pri-mary method used to diagnose prostat...
Prostate specific antigen (PSA) is a common biomarker used to aid detection of prostate cancer (PCa)...
Among different types of cancers which occur in men, prostate cancer is the most commonly occurring ...
BackgroundFor men on active surveillance for prostate cancer, utility of prostate-specific antigen (...
International audienceBACKGROUND:Despite the extensive development of risk prediction models to aid ...
textabstractObjective To assess the value added by percentage of free to total PSA (%fPSA), prostate...
(a) Nomogram for PCa risk prediction of benign prostatic hyperplasia patients. (b) The predicted pro...
International audienceBACKGROUND: Tools for differentiating aggressive and indolent prostate carcino...
textabstractBackground: Prostate-specific antigen (PSA) testing has limited accuracy for the early d...
Prostate cancer (PCa) screening remains a controversial topic. The value of population-based screeni...